Revance Therapeutics, Inc. - COM (RVNC)

Historical Portfolio Holders from Q1 2014 to Q1 2024

All holders as of March 31, 2024
Q1 2024
Type / Class
Equity / COM
Shares, excl. options Q1 2024
81.5 M
Holdings value Q1 2024
$401 M
Value change Q1 2024
+$33.2 M
Grand Portfolio weight change Q1 2024
+0%
Number of holders
174
Number of buys Q1 2024
95
Number of sells Q1 2024
-90
Average buys Q1 2024 %
+0.001%
Average sells Q1 2024 %
0%
CUSIP
761330109
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q1 81.5 M $401 M +$33.2 M $4.92 174
2023 Q4 71.5 M $628 M -$61.7 M $8.79 190
2023 Q3 77.5 M $889 M -$146 M $11.47 184
2023 Q2 81.4 M $2.06 B +$115 M $25.31 208
2023 Q1 76.2 M $2.45 B +$118 M $32.21 216
2022 Q4 73.5 M $1.36 B +$101 M $18.46 186
2022 Q3 67.5 M $1.82 B +$325 M $27.00 179
2022 Q2 55.8 M $771 M +$8.67 M $13.82 154
2022 Q1 54.4 M $1.06 B +$30 M $19.50 145
2021 Q4 52.5 M $856 M -$86.4 M $16.32 140
2021 Q3 54.8 M $1.53 B +$20.2 M $27.86 154
2021 Q2 53.8 M $1.59 B -$21.4 M $29.64 156
2021 Q1 54.6 M $1.52 B +$56.4 M $27.95 146
2020 Q4 52.6 M $1.49 B +$95.5 M $28.34 144
2020 Q3 49.3 M $1.24 B -$27.1 M $25.14 146
2020 Q2 49.8 M $1.21 B +$35.6 M $24.42 134
2020 Q1 49.1 M $726 M -$25.4 M $14.80 118
2019 Q4 50.8 M $824 M +$130 M $16.23 122
2019 Q3 42.6 M $554 M -$12.4 M $13.00 102
2019 Q2 43 M $557 M +$27.1 M $12.97 107
2019 Q1 40.6 M $639 M +$98.5 M $15.76 103
2018 Q4 31.7 M $639 M +$17.6 M $20.13 95
2018 Q3 34 M $845 M -$21.9 M $24.85 106
2018 Q2 27.7 M $761 M +$18.9 M $27.45 105
2018 Q1 34.2 M $1.05 B -$32.7 M $30.80 118
2017 Q4 34.9 M $1.25 B +$167 M $35.75 113
2017 Q3 27.4 M $754 M -$1.52 M $27.55 82
2017 Q2 27.5 M $726 M +$33.7 M $26.40 85
2017 Q1 26.2 M $546 M +$45.4 M $20.80 75
2016 Q4 26.1 M $540 M +$12.2 M $20.70 79
2016 Q3 28.6 M $464 M -$1.08 M $16.21 74
2016 Q2 28.7 M $391 M +$16.9 M $13.60 75
2016 Q1 27.2 M $475 M -$26 M $17.46 81
2015 Q4 27.2 M $929 M +$190 M $34.16 100
2015 Q3 21.6 M $644 M +$32.8 M $29.76 76
2015 Q2 20.4 M $652 M +$15.9 M $31.98 86
2015 Q1 20.5 M $426 M +$18.6 M $20.73 69
2014 Q4 19.8 M $335 M +$8.32 M $16.94 67
2014 Q3 15.7 M $303 M -$45.1 M $19.33 80
2014 Q2 16.4 M $556 M +$155 M $34.00 97
2014 Q1 11.8 M $373 M +$372 M $31.50 65